BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
BeOne Medicines (ONC) reported Q2 2026 revenue of $1.7B, up 30%, and GAAP diluted EPS of $2.05, up 144%. BRUKINSA revenue was $1.2B. Full-year 2026 guidance was raised to $6.6B-$6.8B revenue and $1.0B-$1.1B GAAP operating income. Management cited Phase III MANGROVE and real-world Medicare data.
How this was made
The 30-second read
Why it matters
Traders can update ONC models using the raised 2026 revenue and operating income ranges, and incorporate new Phase III hazard ratios and Medicare real-world death-risk reductions for BRUKINSA-based therapy. The call also flags a Phase III uMRD non-superiority outcome for a different regimen, which may influence expectations for that program’s next steps.
Market read
ONC’s raised 2026 guidance and detailed BRUKINSA efficacy and real-world survival metrics are the primary drivers for near-term trading interest, with program-specific endpoint uncertainty as a counterweight.
What to watch
The guidance raise is tied to BRUKINSA performance and global expansion, so any future patient-start deceleration or competitive pressure could quickly reverse the narrative; also, the $60M tax audit settlement affected reported net income.
Background
This is a Q2 2026 earnings call transcript for BeOne Medicines, covering financial results, raised 2026 guidance, and additional clinical and real-world evidence across hematology and solid tumors.
Ticker impact
BeOne Medicines raised full-year 2026 revenue guidance to $6.6B-$6.8B and operating income to $1.0B-$1.1B on BRUKINSA momentum.
Near-term bias higher on guidance and BRUKINSA/real-world read-through; expect volatility around the uMRD non-superiority detail.
The article discloses multiple primary catalysts: upward financial guidance, specific hazard ratios and real-world death-risk reductions, and a $300M manufacturing expansion, partially offset by a Phase III uMRD non-superiority outcome.
Market effects
Reinforces investor appetite for BTK inhibitor franchises with real-world survival evidence and chemo-free regimen differentiation in hematology.
Highlights continued growth in U.S. and Europe for BRUKINSA, with China TEVIMBRA growth despite competition.
Supports broader biotech sentiment around translating Phase III and Medicare real-world data into commercial durability narratives.
Counterpoint
The CELESTIAL 301 uMRD non-superiority result and reliance on uMRD as a mechanistic endpoint could temper enthusiasm despite hazard-ratio and real-world death-risk claims.
Key entities
- companyBeOne Medicines AG
ONC, reported Q2 results and raised full-year 2026 guidance, alongside new BRUKINSA clinical and real-world evidence.
- productBRUKINSA
Zanubrutinib franchise cited for strong U.S. and global growth and multiple survival-risk reductions in real-world Medicare data.
- clinical_programMANGROVE Phase III
Mantle cell lymphoma study reporting a 0.57 hazard ratio for BRUKINSA plus rituximab superiority versus comparator.
- clinical_programCELESTIAL 301
Study where the zanubrutinib sonrotoclax regimen did not reach statistical superiority in uMRD analysis versus the VO regimen.
- capital_investmentHopewell, New Jersey facility
$300M manufacturing expansion for clinical and commercial-stage production and research.
